Magnetic brain zaps tailored to each patient may boost memory in Alzheimer's

NCT ID NCT03121066

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study investigates whether transcranial magnetic stimulation (TMS) — a non-invasive technique that uses magnetic pulses to stimulate brain areas — can improve thinking, mood, and daily function in people with Alzheimer's disease. Unlike standard TMS, this approach personalizes the stimulation targets based on each person's unique brain connectivity. The trial involves 45 participants aged 60–75 with mild Alzheimer's, who will receive either active TMS, a sham (placebo) treatment, or a conventional non-personalized TMS over two weeks. Researchers will track changes in cognition, mood, and brain activity for up to six months after treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
personalized transcranial magnetic stimulation (TMS) using intermittent theta burst stimulation (iTBS)
What this could lead to
If successful, this approach could offer a non-drug treatment to slow cognitive decline and improve mood in Alzheimer's disease.
What could go wrong
This is a small, early-stage trial with only 45 participants, so results may not apply broadly. The benefits may be modest or temporary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 45 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2027

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of Alzheimer's disease according to the diagnostic criteria of the National Institute on Ageing and the Alzheimer's Association * Ages between 60 and 75 years * Mini Mental State Examination score between 20 and 26 * Global Deterioration Scale score of 3 or 4 * Functional independence for basic daily life activities (part C of the Blessed Scale equal or 0) * Rosen Ischemia Scale less or equal to 4 * Able to read and write * Stable medical and pharmacological state during the 3 consecutive months immediately before the start of the study * Computed Tomography Scan and Magnetic Resonance Imaging in the last 12 months previous to the selection, compatible with the diagnosis of probable Alzheimer's disease in the subjects diagnosed * Absence of clinically significant anomalies in the medical history or clinical laboratory results during the selection * Screening analyses within normal range with the objective of detecting and excluding other causes of dementia in the last 12 months previous to selection. Laboratory values required in order to be considered within the normal range are as follows: complete blood count, thyroid hormones, T4, folic acid, vitamin B12, albumin, transaminase alanine, amino-transferase aspartate, gamma-glutamic transferase, sodium, potassium, urea, creatinine, glucose while fasting * Being treated by Acetylcholinesterase Inhibitors * Signed consent form, previously approved by the Research Ethics Committee Exclusion Criteria: * Knowledge of Spanish or Catalan after the age of 15 * Less than 4 years of schooling * Intellectual deficiency (Premorbid Intelligence Quotient, vocabulary, less than 85) * Not controlled medical conditions or severe mental disorders that may affect the Central Nervous System, including signs of increased intracranial pressure or intracranial lesions * Presenting one or more vascular risks * Medical conditions not controlled that may cause medical emergencies in case the produce convulsions (expel: cardiac malformations, cardiac arrhythmias, asthma, etc.) * Medical history of convulsions, previous diagnosis of epilepsy, previous registry of abnormal electroencephalogram or family history of epilepsy * Severe hearing problems or ringing in the ears (tinnitus) * Severe loss of visual acuity * Moderate or severe depression according to a score \>11 (moderate depression) or 19 (severe depression) in the Geriatric Depression Scale * Presence of tremors or motor control of the dominant upper extremity * Being under pharmacological treatment with medications indicated in the security guidelines. * Drug or alcohol consumption or history of abuse in the last 24 months prior to the study * Implants of metal pieces in the brain (excluding dental fillings) * Either of the following medical devices: pacemaker, implanted medication pumps, vagal nerve stimulators, deep cerebral stimulators, transcutaneous electrical stimulation units, ventriculus-peritoneal derivations, titanium plates, cochlear implants, aneurysm clips, etc… * Negative response towards new technology * Existence of any situation that may cause the subject, according to the principal researcher, not be an adequate candidate for the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.